Gut microbiota and human health are in a symbiotic relation ship and work together to mentain the healthy state. Since the gut microbiota display key immunological and anti oxidative tasks, the altered gut microbiota balance can lead to the development of sistemic inflammation and accelerate the multiple Sclerosis (MS) progression. Some gut bacteria population produce reactive oxygen species (ROS). When these type of bacteria are increased the pro and anti oxidative unbalance appear that alter gut epithelial barrier and trigger systemic inflammation, acting fair away from gut (at brain level) throught gut inflammatory and pro-oxidative signals. Growing evidence show that targeting gut microbiota can be a promising strategy for the MS diseases management. Our hypothesis is that anti oxidant compounds that add multi species beneficial bacteria and promote "good" bacteria growth by fibre substitutes (inulin) decrease ROS production. MS patients (n=25) that received multi species bacteria and inulin and 15 MS patients without supplements were included in this pilot studies. Biomarkers of oxidative stress (e.g protein carbonyl, lipids per oxidation) and anti oxidative response (e.g GSH, SOD, CAT) together with inflammatory biomarkers and intestinal barrier biomarkers (e.g zonulin) was measured in both group. All these biomarker was correlated with MS diseases status and progression using valid scales such as EDSS scale. Results: we showed a reduction of pro-inflammatory cytokines, an improvement of mitochondrial disfunction and decrease in ROS production by multi species bacteria supplements in combination with fibre substitutes such as inulin. These compounds enhance the action of standard therapy in MS people, positively impacting the diseases status and MS progression.